The global immunoglobulins market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to boost the market growth includes the increase in geriatric population and rising number of hemophilic patients, improved immunoglobulin production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield). Moreover, the surge in prevalence of diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia & others is expected to fuel the growth of the global immunoglobulins market during the forecast period. Immunoglobulin, also referred to as antibody is a protein produced by plasma cells and other lymphocytes. It is a complex entity that exerts its immunomodulatory effect on different components of the immune system. It is obtained from the blood through the process of fractionation and is purified for therapeutic and non-therapeutic applications. Different classes of immunoglobulin, IgG, IgA, IgD, IgE, and IgM, are used for the treatment of various immunological and neurological diseases. These immunoglobulins are administered through intravenous and subcutaneous modes of delivery.

Based on application, the immunoglobulin market is divided into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency disease, myasthenia gravis, and others. The hypogammaglobulinemia segment was the highest contributor to the market in 2020 and is anticipated to maintain its dominance during the forecast period. This is attributed to the significant increase in the prevalence of hypogammaglobulinemia disorder across the globe over the years. For instance, hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). Its incidence rate is ~2 per 100,000 population yearly, globally. Based on the mode of delivery, the immunoglobulin market is classified into intravenous and subcutaneous. The intravenous segment accounted for the highest revenue in 2020 and is expected to maintain its dominance during the forecast period. High bioavailability of immunoglobulins and rapid absorption rate offered by intravenous mode of delivery are the factors that supplement the demand for intravenous mode of delivery immunoglobulin. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Baxter International Inc., Grifols S.A, and CSL Behring, among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Immunoglobulins Market Report by Segment

By Product

• IgG
• IgA
• IgM
• IgE
• IgD

By Mode of Delivery

• Intravenous
• Subcutaneous

By Application

• Hypogammaglobulinemi
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Immunodeficiency Disease
• Myasthenia Gravis
• Others

Global Immunoglobulins Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa